Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27413
Abstract: Crovalimab, a novel C5 inhibitor, allows for low‐volume, every‐4‐ week, subcutaneous self‐administration. COMMODORE 1 (NCT04432584) is a phase 3, global, randomized trial evaluating crovalimab versus eculizumab in C5 inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria (PNH).… read more here.
Keywords: crovalimab; inhibitor experienced; crovalimab versus; inhibitor ... See more keywords
Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape
Sign Up to like & getrecommendations! Published in 2024 at "Immunotherapy"
DOI: 10.1080/1750743x.2024.2433410
Abstract: ABSTRACT Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, rare, life-threatening hematopoietic stem cell disorder that causes stem cell-derived cells to be vulnerable to complement-mediated lysis and manifests as hemolytic anemia, thrombosis, and peripheral blood cytopenias.… read more here.
Keywords: crovalimab; treatment; treatment landscape; paroxysmal nocturnal ... See more keywords
Managing transient immune complex reactions in patients with paroxysmal nocturnal hemoglobinuria: clinical observations from the COMMODORE 1 and 2 studies
Sign Up to like & getrecommendations! Published in 2025 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207251359246
Abstract: Background: Crovalimab is a novel C5 inhibitor that enables rapid and sustained C5 inhibition with every 4-week subcutaneous maintenance dosing, with the possibility for self-administration. When switching from another C5 inhibitor (binds to a different… read more here.
Keywords: crovalimab; transient immune; immune complex; patients paroxysmal ... See more keywords
Pregnancy outcomes after crovalimab exposure: Analysis of animal model and clinical trial data suggest no adverse effects in paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3203
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening, complement-mediated hematologic disorder. Pregnancy, often a complement-activating event, is associated with poor outcomes in patients with untreated PNH and other complement-mediated diseases. Crovalimab (PiaSky®) is a next-generation… read more here.
Keywords: crovalimab; treatment; clinical trial; pregnancy ... See more keywords